FCRL5 and myasthenia gravis: We showed that in naïve MuSK-MG, FCRL5 inversely correlated with CD95 (r = -0.74, p = 0.037) and CD21 (r = -0.74, p = 0.037) (Figure 7C) which was maintained in the rituximab treated MuSK-MG (Supplementary Figure 3).